Elevation Oncology Stock (NASDAQ:ELEV)

Forecast Revenue Ownership Financials Chart

Previous Close

$0.58

52W Range

$0.44 - $5.83

50D Avg

$0.58

200D Avg

$2.49

Market Cap

$34.35M

Avg Vol (3M)

$718.75K

Beta

1.25

Div Yield

-

ELEV Company Profile

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

29

IPO Date

Jun 25, 2021

Website

ELEV Performance

ELEV Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-45.45M	$-94.55M	$-32.05M
Net Income	$-45.70M	$-95.08M	$-32.04M
EBITDA	$-45.45M	$-94.55M	$-32.03M
Basic EPS	-	$-4.09	$-2.64
Diluted EPS	-	$-4.09	$-2.64

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
CWBR	CohBar, Inc.
AVRO	AVROBIO, Inc.
OCEA	Ocean Biomedical, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
ZURA	Zura Bio Limited
ENVB	Enveric Biosciences, Inc.